Romain Clement | CEO
ArcaScience
Romain Clément is the CEO of ArcaScience, a healthtech company founded in 2018 whose AI platform is the very first to automate benefit-risk assessment, the decision at the heart of every drug approval. By reading the full evidence base behind a molecule and structuring it the way regulators require, ArcaScience turns months of manual synthesis into a living, source-linked analysis, helping sponsors accelerate R&D, strengthen treatment safety, and better target patients. He also teaches at Paris I Panthéon-Sorbonne, where he lectures on philosophy contextualized by the industrialization of AI, data pipelines, and the impact of evidence-driven decision-making.
Appearances:
Day 1: 23rd September @ 14:40
Risk Management 2 Panel 4 – Structured Benefit-Risk in Practice: From Decision Framework to a Live, Benchmarked Assessment
This session shows how AI can operationalise structured benefit-risk assessments through CIOMS XII and current FDA and EMA recommendations while preserving traceability and expert judgement.
2026 analyses estimate a 2 to 5 percentage point difference in approval probability linked to assessment quality and timing. This conference will go in-depth into a new benchmark exploring such claims and comparing expert VS frontier AI models.
An undisclosed molecule will be assessed live, from decision context to structured regulatory output.
Get Involved At
World Patient Safety Congress
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events